FRENCH CLINICAL TRIAL WITH POSITIVE OUTCOMES FOR NASH: LYON, France–( BUSINESS WIRE )– POXEL SA (Euronext: POXEL – FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced positive results from a PXL770 four-week placebo-controlled PK/PD study in 16 likely-NASH patients with insulin […]
Click here to view original web page at www.businesswire.com